See the DrugPatentWatch profile for rivaroxaban

Rivaroxaban, also known by its brand name Xarelto, is an anticoagulant medication that is used to prevent blood clots. In regards to its patent status, the sources provided shed light on different aspects.

According to the first source, DrugPatentWatch, rivaroxaban's composition patent expired on November 26, 2019. This means that other pharmaceutical companies are now able to produce generic versions of the drug. However, it is important to note that there may still be other patents associated with rivaroxaban, such as formulation or method of use patents, that could provide additional protection.

The second source, Reuters, reports that Bayer, the pharmaceutical company that developed Xarelto, has won a patent extension for the drug in the European Union. This extension grants Bayer an additional six months of patent protection, allowing them to exclusively market and sell Xarelto until May 2024. The extension was granted based on the drug's pediatric use, as it is being studied for the prevention of blood clots in children.

The third source, a study published on PubMed, does not specifically address the patent status of rivaroxaban. Instead, it focuses on the efficacy and safety of the drug in preventing blood clots in patients with atrial fibrillation. The study concludes that rivaroxaban is an effective and safe alternative to warfarin, another anticoagulant medication.

In summary, rivaroxaban's composition patent has expired, allowing for the production of generic versions of the drug. However, Bayer has obtained a patent extension in the European Union based on the drug's pediatric use, granting them exclusive rights to market and sell Xarelto until May 2024. It is important to consult the official patent databases or legal sources for the most up-to-date and accurate information regarding rivaroxaban's patent status.

Sources:
[1] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/RIVAROXABAN
[2] Reuters: https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-wins-eu-patent-extension-best-selling-xarelto-drug-2021-10-29/
[3] PubMed: https://pubmed.ncbi.nlm.nih.gov/30274772/